Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis

Key Inclusion Criteria:

• Able to understand and communicate with the investigator, willing and capable tocomply with all study procedures, and provide written signed and dated informedconsent (personally or by a witness) before any assessment is performed.

• Aged 18 to 50 years inclusive.

• New-onset plaque psoriasis with appearance of the first psoriasis plaques within thelast 12 months before randomization and naïve to any systemic treatment andphototherapy (Arm A1, Arm A2, and Arm B1). Episodes of mild psoriasis, whichoccurred at least 3 years before screening and resolved spontaneously within 6months will be accepted.

• Chronic plaque psoriasis with appearance of the first psoriasis symptoms 5 years orlonger and intolerance or inadequate response to phototherapy or any systemictreatment including biologicals, except for IL-17A inhibitors (Arm C1 and Arm C2).

• Moderate to severe plaque psoriasis defined at screening and baseline by PASI >= 10,and body surface area (BSA) >= 10%, and IGA mod 2011 >= 3.

Key Exclusion Criteria:

• Forms of psoriasis other than plaque-type (e.g., pustular, erythrodermic, guttate,light sensitive, and drug induced).

• Ongoing use of prohibited treatments.

• Previous treatment with phototherapy or any systemic treatment.

• Pregnant or nursing (lactating) women.

• Women of childbearing potential, defined as all women physiologically capable ofbecoming pregnant, unless they are using effective methods of contraception duringthe Treatment period or longer if required by locally approved prescribinginformation (e.g., 20 weeks in the EU and countries where applicable forsecukinumab).